Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.

Ulf M GeisenDennis K BernerFlorian TranMelike SümbülLena VullriedeMaria CiripoiHayley M ReidAnnika SchaffarzykAnn C LongardtJeanette FranzenburgPaula HoffJan H SchirmerRainald ZeunerAnette FriedrichsAndrea SteinbachChristine KniesRobert Daniel Heinrich MarkewitzPeter J MorrisonSascha GerdesStefan SchreiberBimba Franziska Hoyer

Published in: Annals of the rheumatic diseases (2021)

We show that SARS-CoV-2 mRNA vaccines lead to development of antibodies in immunosuppressed patients without considerable side effects or induction of disease flares. Despite the small size of this cohort, we were able to demonstrate the efficiency and safety of mRNA vaccines in our cohort.

Keyphrases

sars cov
end stage renal disease
respiratory syndrome coronavirus
newly diagnosed
ejection fraction
binding protein
chronic kidney disease
oxidative stress
peritoneal dialysis
stem cells
patient reported outcomes
bone marrow
cell therapy
patient reported